Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Investing Offers a Free Lunch, Says This Wall Street Veteran. Take It.
George Gatch, CEO of J.P. Morgan Asset Management, advises clients to diversify their holdings and stay in the market.
Washington Takes Aim at DeepSeek
Lawmakers are said to be working on a bill to block the Chinese chatbot app from government devices, underscoring concerns ...
How To Fund A U.S. Sovereign Wealth Fund?
Read about the creation of the first-ever American sovereign wealth fund and its potential funding mechanisms.
UnitedHealth raises concerns with SEC over Ackman post on X
I would not be surprised to find that the company’s profitability is massively overstated due to its denial of medically ...
Bernstein Sticks to Their Buy Rating for UnitedHealth (UNH)
In a report released yesterday, Lance Wilkes from Bernstein maintained a Buy rating on UnitedHealth (UNH – Research Report), with a price ...
Twitter debt: the new Trump trade
Plus, the food conglomerate owner of Krispy Kreme buys an insurance company and a distressed-debt battle in Japan ...
UnitedHealth Shares Fall After Ackman’s Social-Media Post, Company Notifies SEC
UnitedHealth shares fell more than 4% on Wednesday before finishing down 1%, a day after hedge-fund manager Bill Ackman wrote a post on social media that said the insurer could be overstating its ...
Trump Administration Negotiates With Chevron On Company's Venezuela Business
The second Trump Administration has brought a flurry of foreign policy changes to the federal government. Its latest action ...
UnitedHealth raises concerns over Bill Ackman's post on X with SEC
UnitedHealth has reached out to the U.S. Securities and Exchange Commission about billionaire investor Bill Ackman's now-deleted post on social media platform X that said he would take a short ...